Tenaya Therapeutics Inc (TNYA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TNYA quarterly Cash Flow →
The table below presents a historical view of Tenaya Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2020)
Operating Activities
Income-90.60
Depreciation & amortization8.44
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation13.05
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Operating Lease Expense-
Change In Fair Value Of Convertible Preferred Stock Tranche Liability-
Increase Decrease In Prepaid Expense And Other Current Assets0.55
Increase Decrease In Accrued Liabilities And Other Current Liabilities0.53
Increase Decrease In Deferred Rent And Other Lease Liabilities-
Amortization Of Premium On Marketable Securities0.41
Increase Decrease In Operating Lease Liability2.47
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.43
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.67
Other Noncash Income (Expense)0.42
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.78
Discontinued operations0.00
Net Cash flow from Operating Activities-68.26
Investing Activities
Capital Expenditures-0.62
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities45.74
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Proceeds From Sales Of Marketable Securities10.96
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities56.08
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock107.35
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.89
Proceeds From Repayments On Notes Receivable From Stockholders-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations4.74
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Deferred Offering Costs Related To Initial Public Offering Included In Accounts Payable-
Capital Expenditures Incurred But Not Yet Paid0.06
Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan0.14
Proceeds From Exercises Of Pre Funded Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities108.41
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-68.88
Total Cash Flow96.22
4 historic quarters locked

Sign in to unlock the full Tenaya Therapeutics Inc cash flow history.

About Tenaya Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-102252

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License